Evidence map›Paper›PMID 21216274›Full record

ArticleExperimental hematology2011

Mad2 haploinsufficiency protects hematopoietic progenitor cells subjected to cell-cycle stress in vivo and to inhibition of redox function of Ape1/Ref-1 in vitro.

Sara L Rohrabaugh, Giao Hangoc, Mark R Kelley, Hal E Broxmeyer

Abstract read
In one paragraph

Article in Experimental hematology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Sara L RohrabaughDepartment of Microbiology and Immunology, Indiana University School of Medicine, Indianapolis, IN 46202, USA.
Giao Hangoc
Mark R Kelley
Hal E Broxmeyer
Indiana University – Purdue University Indianapolis · USIndiana University School of Medicine

Funding

VectorP01HL053586 · NHLBI · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI CORNETTA, KENNETH · 1995 to 2009
$16.0M
MECHANISMS OF SYNERGISTIC REGULATION OF STEM/PROGENITORSR01HL056416 · NHLBI · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI BROXMEYER, HAL E. · 1996 to 2017
$6.0M
Cytokine Enhancement of Myeloid Progenitor Cell SurvivalR01HL067384 · NHLBI · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI BROXMEYER, HAL E. · 2001 to 2014
$4.6M
The Role of Ape1 in Neurotoxicity of Cancer TreatmentsR01CA121168 · NCI · INDIANA UNIVERSITY INDIANAPOLIS · PI KELLEY, MARK R. · 2008 to 2012
$2.4M
Cancer Biology Training ProgramT32CA111198 · NCI · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI NAKSHATRI, HARIKRISHNA · 2005 to 2009
$1.8M
Imbalancing DNA BER to enhance Ovarian Tumor SensitivityR01CA106298 · NCI · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI KELLEY, MARK R. · 2004 to 2008
$1.5M
Mechanism of Redox Regulation by Ape1/Ref-1R01CA114571 · NCI · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI GEORGIADIS, MILLIE M · 2006 to 2010
$1.2M
Therapeutic/Mechanistic Role of Ape1 in Germ Cell TumorsR01CA094025 · NCI · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI KELLEY, MARK R. · 2003 to 2007
$1.1M
NCI NIH HHS CA106298NCI NIH HHS CA114571NCI NIH HHS CA 121168NCI NIH HHS CA94025NCI NIH HHS R01 CA094025NCI NIH HHS R01 CA106298NCI NIH HHS R01 CA114571NCI NIH HHS R01 CA121168NCI NIH HHS T32 CA 111198NCI NIH HHS T32 CA111198NHLBI NIH HHS P01 HL053586NHLBI NIH HHS P01 HL 53586NHLBI NIH HHS R01 HL056416NHLBI NIH HHS R01 HL067384NHLBI NIH HHS R01 HL 56416NHLBI NIH HHS R01 HL 67384
6 · The paper itself

Abstract

objectiveCell-cycle checkpoints guarantee movement through the cell cycle. Mitotic arrest deficiency 2 (Mad2), a mitotic checkpoint protein, appears crucial for generating the wait anaphase signal to prevent onset of anaphase. We evaluated effects of Mad2 haploinsufficiency on hematopoietic stem (HSC) and progenitor (HPC) function in response to stress. MATERIALS AND

methodsWe studied effects of Mad2(+/-) on in vivo recovery of bone marrow HPC from cytotoxic effects and also effects of cytostatic agents on HPC growth in vitro using Mad2(+/-) mice.

resultsMad2(+/-) HPCs were protected from cytotoxic effects in vivo of a cell-cycle-specific agent, Ara-C, events consistent with Mad2(+/-) HPCs being in a slow or noncycling state, but not from recovery of functional HPC after treatment with non-cycle-specific cyclophosphamide or sublethal irradiation. There were no differences in phenotyped HSCs in Mad2(+/-) &Mad2(+/+) mice, information confirmed by no changes in short- or long-term repopulating HSC assay. To better understand Mad2(+/-) HPC function, E3330, a cytostatic agent, was used to assess redox function of Ape1/Ref-1; colony growth was examined under 5% and 20% O(2) tension. Mad2(+/-) HPCs were less responsive to E3330 than Mad2(+/+) HPCs, and E3330 was more effective under lowered O(2) tension. Mad2(+/-) HPCs were not enhanced at lowered oxygen, as were Mad2(+/+) HPCs.

conclusionsOur studies have unexpectedly found that Mad2 haploinsufficiency is protective in the presence of a cycle-specific DNA synthesis agent in vivo, and Ape1/Ref-1 inhibitor in vitro.

Indexed as

HaploinsufficiencyAnimalsBenzoquinonesCell CycleCell Cycle ProteinsColony-Forming Units AssayCyclophosphamideCytarabineDNA-(Apurinic or Apyrimidinic Site) LyaseFemaleHematopoietic Stem CellsHematopoietic Stem Cell TransplantationImmunosuppressive AgentsMad2 ProteinsMaleMiceApex1 protein, mouseBenzoquinonesCell Cycle ProteinsCyclophosphamideCytarabineDNA-(Apurinic or Apyrimidinic Site) LyaseE 3330Immunosuppressive AgentsMad2l1 protein, mouseMad2 ProteinsOxygenPropionates

Identifiers

PMID21216274
PMCPMC3062656
OpenAlexW2069681027

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.